Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)

Emerging Microbes and Infections

Volumn 4, Issue 6, 2015, Pages

  Lu, Lu ^a   Xia, Shuai ^a   Ying, Tianlei ^a   Jiang, Shibo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE HR2P; PEPTIDE HR2P M2; UNCLASSIFIED DRUG; VIRUS VACCINE; ANTIVIRUS AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; MONOCLONAL ANTIBODY; VIRUS FUSION INHIBITOR;

DRUG MECHANISM; HUMAN; LETTER; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; VIRAL UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; IMMUNOLOGY; PROTEIN DOMAIN;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; DRUG SYNERGISM; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PROTEIN DOMAINS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL FUSION PROTEIN INHIBITORS;

EID: 84989347295     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2015.37     Document Type: Letter

References (15)

1. Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): Challenges in identifying its source and controlling its spread. Microbes Infect 2013; 15: 625-629.
2. Hotez PJ, Bottazzi ME, Tseng CT et al. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect 2014; 16: 529-531.
3. Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993; 365: 113.
4. Liu S, Xiao G, Chen Y et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-Associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004; 363: 938-947.
5. Lu L, Liu Q, Zhu Y et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014; 5: 3067.
6. Zhao J, Li K, Wohlford-Lenane C et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111: 4970-4975.
7. Channappanavar R, Lu L, Xia S et al. Protective effect of intranasal regimens containing peptidic MERS-CoV fusion inhibitor against MERS-CoV infection. J Infect Dis 2015; doi: 10.1093/infdis/jiV325.
8. Ying T, Du L, Ju TWet al. Exceptionally potent neutralization of MERS-CoV by human monoclonal antibodies. J Virol 2014; 88: 7796-7805.
9. Jiang L, Wang N, Zuo T et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014; 6: 234ra59.
10. Tang XC, Agnihothram SS, Jiao Y et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 2014; 111: E2018-E2026.
11. Du L, Zhao G, Yang Y et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in MERS-CoV spike protein. J Virol 2014; 88: 7045-7053.
12. Ying T, Li H, Lu L, Dimitrov DS, Jiang S. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect 2015; 17: 142-148.
13. Geisbert TW, Mire CE, Geisbert JB et al. Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody. Sci Transl Med 2014; 6: 242ra82.
14. Geisbert TW. Medical research: Ebola therapy protects severely ill monkeys. Nature 2014; 514: 41-43.
15. Lyon GM, Mehta AK, Varkey JB et al. Clinical Care of Two Patients with Ebola Virus Disease in the United States. N Engl J Med 2014; 371: 2402-2409.